EUCTR2005-000619-85-GB
Active, not recruiting
Phase 1
The relationship between genetic polymorphisms in the organic cation transporter genes and the pharmacokinetics and pharmacodynamics of metformin - The genetics of metformin excretion
The University of Liverpool0 sites200 target enrollmentMay 4, 2005
ConditionsType 2 diabetes mellitus
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Type 2 diabetes mellitus
- Sponsor
- The University of Liverpool
- Enrollment
- 200
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subject is aged between 25 and 85 years of age inclusive.
- •2\. Subject has given signed informed consent (written and witnessed).
- •3\. Subject has a diagnosis of type 2 diabetes mellitus, regardless of how and when that diagnosis was established.
- •4\. Subject’s anti\-hyperglycaemic medication consists of metformin monotherapy, at a dosage of 500mg three times daily and that dosage has been established for a period of at least 3 months.
- •5\. Subject has not missed any metformin doses for a period of at least 5 days and compliance has been assessed through a validated compliance questionnaire.
- •6\. Subject is able to recall at least approximate timing of dosing (within 30 minutes).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •1\. Subject is, in the opinion of the Investigator, not suitable to participate in the study.
- •2\. Subject has a diagnosis of pernicious anaemia.
- •3\. Subject is also prescribed additional anti\-hyperglycaemic medication such as sulphonylureas, meglitinide analogues, thiazolidinediones or insulin.
- •4\. Subject has taken any known inhibitor of OCT1 or OCT2, such as amantadine, cimetidine, clonidine, desipramine, midazolam, procainamide, quinidine, quinine, or verapamil in the last 4 weeks.
- •5\. Subject has participated in strenuous physical activity, defined as more than typical walking pace, for a period of 8 hours prior to study entry.
- •6\. Subject has an alcohol intake greater than the recommended weekly safe drinking limits (\>21 units in men; \>14 units in women).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Functional linkage between the genetic polymorphisms of innate immunity regulatory genes and diseases in Japanese subjects.heart disease,connective tissue disease, uveitis, Adult T cell Leukemia, human T-cell leukemia virus type 1-carriers, healthy subjectJPRN-UMIN000008456Department of Microbiology, Oita University Faculty of Medicine520
Recruiting
Phase 1
Study for correlation between gene polymorphism of GRM5, Schizophrenia and Traditional Chinese Medicine SyndromeschizophreniaITMCTR2000003214Tongde Hospital of Zhejiang Province
Completed
Not Applicable
Association between Genetic Polymorphisms of Core Clock Genes and 24-hour IOP-related profile in Japanese Normal-Tension Glaucomaormal tension glaucomaJPRN-UMIN000022741Kanazawa University100
Completed
Not Applicable
The Relationship of single nucleotide polymorphisms in the Interleukin-7 receptor-alpha gene to CD4+ immune recovery in HIV infected patients who begin antiretroviral treatment with HAARTThe determinants of immune recovery following institution of Highly Active Antiretroviral Treatment in HIV infected patientsInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12605000495628HMRC110
Recruiting
Not Applicable
Elucidation of genes involved in individual differences in ondansetron sensitivityPatients undergoing orthognathic surgeryJPRN-UMIN000051727Tokyo Dental College100